 | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.221.150 |
| Chemical and physical data | |
| Formula | C19H26ClNO6 |
| Molar mass | 399.87 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Arbaclofen placarbil (/ɑːrˈbækloʊfɛnpləˈkɑːrbɪl/ar-BAK-loh-fen plə-KAR-bil, also known asXP19986) is aprodrug ofR-baclofen. Arbaclofen placarbil possesses more favorable pharmacokinetic profile than baclofen, with less fluctuations in plasma drug levels. It was being developed as a potential treatment for patients withGERD and spasticity due tomultiple sclerosis; however, in May 2013 XenoPort announced the termination of development because of unsuccessful results inphase III clinical trials.[1]
It is being developed as an addiction medicine to treat alcoholism.[2] It is also studied as a potential therapeutic for some autistic subjects.[3]
 | Thisdrug article relating to thegastrointestinal system is astub. You can help Wikipedia byexpanding it. |
 | Thisdrug article relating to themusculoskeletal system is astub. You can help Wikipedia byexpanding it. |
